RSNA 2021 Molecular Imaging Preview

PET tracers can verify patient response to HIFU treatment

By Will Morton, AuntMinnie.com staff writer

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-5 | Room N226
In this molecular oncologic imaging presentation, researchers will report on the use of gallium-68-based radiotracers to assess response to high-intensity focused ultrasound (HIFU) therapy in prostate cancer patients.

HIFU is a noninvasive local treatment that uses thermal energy to ablate prostate cancer lesions. Long-term results for tumor control and oncologic outcomes are sparse, according to researchers at Stanford University in California.

Postdoctoral nuclear medicine fellow Dr. Heying Duan will discuss a novel approach in 14 men with newly diagnosed prostate cancer who underwent focal ablation with HIFU. The researchers performed imaging with either gallium-68 PSMA-PET/MRI prior to surgery, followed by gallium-68 RM2 PET/MRI within two weeks, or vice versa.

Preliminary results showed that both Ga-68 PSMA and Ga-68 RM2 PET/MRI identified the dominant lesion for HIFU ablation prior to treatment and accurately verified response to treatment in 88.9% of patients.

Check out this session for the details and a discussion of next steps.


Last Updated np 11/19/2021 11:33:48 AM